Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 2/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TLR2 | O60603 | 1/20 | 0.33 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 2/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31482347 | 1.00 | KLK7 (0.35) | KLK7SCN9ACYP3A4TLR2TLR1 | |
| SCHEMBL3745036 | 1.00 | KLK7 (0.35) | KLK7SCN9ACYP3A4TLR2TLR1 | |
| SCHEMBL25717615 | 0.94 | KLK7 (0.35) | KLK7SCN9ACYP3A4TLR2TLR1 | |
| SCHEMBL18207164 | 0.89 | KDM4E (0.35) | MEN1ALDH1A1KMT2AMAPK1 | |
| SCHEMBL18207163 | 0.89 | KDM4E (0.35) | MEN1ALDH1A1KMT2AMAPK1 | |
| SCHEMBL18218809 | 0.89 | CPB2 (0.33) | CPB2 | |
| SCHEMBL3439706 | 0.85 | KLK5 (0.41) | CPB2TACR1CTSSCTSLCTSB | |
| SCHEMBL9838791 | 0.85 | KLK5 (0.41) | CPB2TACR1CTSSCTSLCTSB | |
| SCHEMBL31001585 | 0.85 | CPB2 (0.31) | CPB2 | |
| SCHEMBL13650201 | 0.82 | ITGB3 (0.45) | MAPK1CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362015-B2 | Aminoacyl prodrug derivatives and medicaments for treatment of thromboembolic disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-01-29 | — | — | US | disclosed |
| US-20100292230-A1 | Aminoacyl prodrug derivatives and medicaments for treatment of thromboembolic disorders | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292230-A1 | Aminoacyl prodrug derivatives and medicaments for treatment of thromboembolic disorders | AADAC, AADAT, DNPEP | KLK7 4392/4885SCN9A 3029/4885CYP3A4 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.